Key result
Complete revascularisation cuts MACE ~30% compared with culprit-only PCI.
Why the study?
Approximately 40–65% of STEMI patients present with multivessel coronary artery disease, and the comparative benefits of complete versus culprit-only revascularisation remain to be clarified.
Does complete revascularisation reduce major adverse cardiovascular events in patients with ST-elevation myocardial infarction and multivessel coronary artery disease?
Meta-Analysis (n=22,000)
Does complete revascularisation reduce major adverse cardiovascular events in patients with ST-elevation myocardial infarction and multivessel coronary artery disease?
Relative Risk: 0.7 (95% CI 0.61–0.8)
p-value: p=<0.0001
Complete revascularisation significantly improves clinical outcomes (reduces MACE) compared to culprit-only PCI in patients with STEMI and multivessel disease.
Supports complete revascularization in multivessel STEMI; reinforces consensus from prior RCTs and bolsters guideline recommendations.
Background and Aims ST-elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality worldwide. Approximately 40–65% of patients present with multivessel coronary artery disease, which is associated with poorer clinical outcomes. While primary percutaneous coronary intervention (PCI) has traditionally focused on the culprit lesion, emerging evidence suggests that complete revascularisation may provide additional benefit. This study aimed to compare the outcomes of complete versus culprit-only revascularisation. Methods A systematic review and random-effects meta-analysis were conducted using PubMed, Scopus, ProQuest, and ScienceDirect databases up to 2025. Randomised and observational studies involving patients with STEMI and multivessel disease were included. Studies comparing complete versus culprit-only PCI were analysed, with major adverse cardiovascular events (MACE) as the primary outcome. Results Eight high-quality studies involving approximately 22,000 patients were included. Complete revascularisation significantly reduced MACE by 30% compared with culprit-only PCI (RR 0.70, 95% CI 0.61–0.80; p<0.0001). Substantial heterogeneity was observed (I²=86%), likely reflecting differences in revascularisation timing and patient risk profiles. However, the direction of effect consistently favoured complete revascularisation across studies. Conclusion Complete revascularisation significantly improves clinical outcomes in patients with STEMI and multivessel coronary artery disease. Despite heterogeneity, the evidence consistently supports its superiority over culprit-only PCI, reinforcing current guideline recommendations and its role as the preferred strategy to improve long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2026) conducted a meta-analysis in ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (n=22,000). Complete revascularisation vs. Culprit-only PCI was evaluated on major adverse cardiovascular events (MACE) (RR 0.70, 95% CI 0.61-0.80, p=<0.0001). Complete revascularisation significantly reduced major adverse cardiovascular events compared with culprit-only PCI (RR 0.70; 95% CI 0.61-0.80; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: